<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998566</url>
  </required_header>
  <id_info>
    <org_study_id>AGX17-001-US</org_study_id>
    <nct_id>NCT03998566</nct_id>
  </id_info>
  <brief_title>Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer</brief_title>
  <official_title>Early Feasibility Study For Evaluation Of The TraceIT® Tissue Spacer For Creating Space Between The Duodenum And Pancreas In Patients With Localized Pancreatic Cancer Undergoing Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An early feasibility study to evaluate feasibility, radiotherapy benefits and safety when&#xD;
      using TraceIT tissue spacer to create space between pancreas and duodenum in patients with&#xD;
      localized Pancreatic Cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2018</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ability to place TraceIT Tissue Spacer and create space between the duodenum and head of pancreas in patients undergoing image-guided radiotherapy for pancreatic adenocarcinoma.</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>TraceIT Tissue Spacer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TraceIT Tissue Spacer implantation</intervention_name>
    <description>The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.</description>
    <arm_group_label>TraceIT Tissue Spacer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old&#xD;
&#xD;
          2. Biopsy-confirmed localized pancreatic cancer in the head or neck of the pancreas as&#xD;
             defined by the NCCN guidelines&#xD;
&#xD;
          3. Tumor is clearly delineable from duodenum and no clear evidence of invasion of the&#xD;
             duodenum is seen at time of EUS performed for either diagnosis or fiducial placement.&#xD;
&#xD;
          4. Subject is able to comply with motion management guidelines.&#xD;
&#xD;
          5. Radiotherapy or chemoradiotherapy for treatment of the disease is indicated.&#xD;
&#xD;
          6. In Investigator's opinion, medically fit to undergo endoscopy for fiducial marker&#xD;
             implantation and TraceIT administration.&#xD;
&#xD;
          7. Subjects Screening/Baseline laboratory testing must meet the following laboratory&#xD;
             value criteria:&#xD;
&#xD;
               1. White blood cell count: ≥ 3.0 x 109/L&#xD;
&#xD;
               2. Absolute neutrophil count (ANC): ≥ 1.5 x 109/L&#xD;
&#xD;
               3. Platelets: ≥ 100 x 109/L&#xD;
&#xD;
               4. Total bilirubin: ≤ 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
               5. AST and ALT: ≤ 3.0 times institutional upper normal limit&#xD;
&#xD;
               6. Serum creatinine: &lt; 1.5 times ULN e&#xD;
&#xD;
               7. INR: &lt; 1.5&#xD;
&#xD;
               8. Serum pregnancy: Negative&#xD;
&#xD;
               9. Hemoglobin: ≥ 8.0 g/dl&#xD;
&#xD;
          8. Zubrod Performance Status 0-2&#xD;
&#xD;
          9. Subject or authorized representative, has been informed of the nature of the study and&#xD;
             has provided written informed consent, approved by the appropriate Institutional&#xD;
             Review Board (IRB) of the respective clinical site.&#xD;
&#xD;
         10. Life expectancy of at least 9 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients for whom radiotherapy is contraindicated&#xD;
&#xD;
          2. Previous thoracic or abdominal radiotherapy&#xD;
&#xD;
          3. Any GI abnormality that would interfere with the ability to access the injection site&#xD;
&#xD;
          4. Presence of tumor invasion of the duodenum detected on EUS at time of biopsy&#xD;
&#xD;
          5. Previous Whipple procedure or other resection of pancreatic tumor prior to screening&#xD;
&#xD;
          6. Active gastroduodenal ulcer or uncontrolled watery diarrhea&#xD;
&#xD;
          7. History of Chronic Renal Failure.&#xD;
&#xD;
          8. Documented history of uncontrolled diabetes (i.e., symptomatic hyperglycemia that&#xD;
             cannot be medically managed, fasting blood glucose level above 300 mg/dL, and/or&#xD;
             frequent swings between hyperglycemia and hypoglycemia)&#xD;
&#xD;
          9. Currently enrolled in another investigational drug or device trial that clinically&#xD;
             interferes with this study.&#xD;
&#xD;
         10. Unable to comply with the study requirements or follow-up schedule.&#xD;
&#xD;
         11. Any condition or comorbidity that the Investigator believes would interfere with the&#xD;
             intent of the study or would make participation not in the best interest of the&#xD;
             subject.&#xD;
&#xD;
         12. Women who are pregnant or breast-feeding; women of child-bearing age must use&#xD;
             contraceptives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Radiation</keyword>
  <keyword>SBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

